EVALUATION OF THE EFFICACY OF TOLCAPONE AS A GENOTYPE-BASED TARGETED COGNITIVE ENHANCER IN SCHIZOPHRENIA, BASED ON THE POLYMORPHISM RS4680

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-511433-35-00

Acronym

rs4680-tolcapona

Enrollment

Registered

2024-05-14

Start date

Unknown

Completion date

Unknown

Last updated

2024-05-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

SCHIZOPHRENIA

Brief summary

Performance in the DPX cognitive test and in the modified MATRICS battery (number of errors and response times) 2) Brain activation elicited during functional brain MRI (fMRI) (relative degree of activation of different brain regions): BOLD response

Detailed description

Efficacy: scores on clinical scales (PANSS, NSA-16, BPRS, ICG, GAF, Ham A, Ham D, Psychosis Severity Dimensions)., Patient reported outcomes: POMS, visual analogue scales, Plasma homocysteine value

Interventions

DRUGTasmar 100 mg film-coated tablets

Eligibility

Sex/Gender

All

Age

18 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
Performance in the DPX cognitive test and in the modified MATRICS battery (number of errors and response times) 2) Brain activation elicited during functional brain MRI (fMRI) (relative degree of activation of different brain regions): BOLD response	—

Secondary

Measure	Time frame
Efficacy: scores on clinical scales (PANSS, NSA-16, BPRS, ICG, GAF, Ham A, Ham D, Psychosis Severity Dimensions)., Patient reported outcomes: POMS, visual analogue scales, Plasma homocysteine value	—

Countries

Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026